9BU6 image
Entry Detail
PDB ID:
9BU6
EMDB ID:
Title:
Vaccine elicited Fab C968.180 with influenza H10 JD13 HA trimer
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2024-05-16
Release Date:
2024-11-27
Method Details:
Experimental Method:
Resolution:
3.65 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Fab C968.180 heavy chain
Chain IDs:A, E, I
Chain Length:131
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Fab C968.180 light chain
Chain IDs:B, F, J
Chain Length:108
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Hemagglutinin HA1
Chain IDs:C, G, K
Chain Length:325
Number of Molecules:3
Biological Source:Influenza A virus
Polymer Type:polypeptide(L)
Description:Hemagglutinin HA2
Chain IDs:D, H, L
Chain Length:230
Number of Molecules:3
Biological Source:Influenza A virus
Ligand Molecules
Primary Citation
Vaccination with different group 2 influenza subtypes alters epitope targeting and breadth of hemagglutinin stem-specific human B cells.
Sci Transl Med 17 eadr8373 eadr8373 (2025)
PMID: 39742506 DOI: 10.1126/scitranslmed.adr8373

Abstact

The conserved influenza hemagglutinin stem, which is a target of cross-neutralizing antibodies, is now used in vaccine strategies focused on protecting against influenza pandemics. Antibody responses to group 1 stem have been extensively characterized, but little is known about group 2. Here, we characterized the stem-specific repertoire of individuals vaccinated with one of three group 2 influenza subtypes (H3, H7, or H10). Epitope mapping revealed two epitope supersites on the group 2 stem. Antibodies targeting the central epitope were broadly cross-reactive, whereas antibodies targeting the lower epitope had narrower breadth but higher potency against H3 subtypes. The ratio of B cells targeting each of the supersites varied with the vaccine subtype, leading to differences in the cross-reactivity of the B cell response. Our findings suggest that vaccine strategies targeting both group 2 stem epitopes would be complementary, eliciting broader and more potent protection against both seasonal and pandemic influenza strains.

Legend

Protein

Chemical

Disease

Primary Citation of related structures